TY  - BOOK
AU  - Jordan, Marion H
AU  - Shupp, Jeffrey W
TI  - Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury
SN  - 0749-8047
PY  - 2015///
KW  - *Adrenergic beta-Antagonists/tu [Therapeutic Use]
KW  - *Burns/co [Complications]
KW  - *Catechol O-Methyltransferase/ge [Genetics]
KW  - *Pain
KW  - *Polymorphism, Single Nucleotide/ge [Genetics]
KW  - *Propranolol/tu [Therapeutic Use]
KW  - Adult
KW  - Burn Units
KW  - Burns/dt [Drug Therapy]
KW  - Double-Blind Method
KW  - Female
KW  - Follow-Up Studies
KW  - Genotype
KW  - Humans
KW  - Male
KW  - Pain Measurement
KW  - Pain/dt [Drug Therapy]
KW  - Pain/et [Etiology]
KW  - Pain/ge [Genetics]
KW  - Patient Compliance/px [Psychology]
KW  - Pilot Projects
KW  - Time Factors
KW  - Treatment Outcome
KW  - Young Adult
KW  - MedStar Washington Hospital Center
KW  - Surgery/Burn Services
N1  - Available online from MWHC library: 1996 - present
N2  - BACKGROUND: Results of previous studies suggest that beta-adrenoreceptor activation may augment pain, and that beta-adrenoreceptor antagonists may be effective in reducing pain, particularly in individuals not homozygous for the catechol-O-methyltransferase (COMT) high-activity haplotype; CONCLUSIONS: Genotype-specific pain medication interventions are feasible in hospitalized burn patients. Propranolol is unlikely to be a useful analgesic during the first few weeks after burn injury; MATERIALS AND METHODS: Consenting patients admitted for thermal burn injury at participating burn centers were genotyped; those who were not high-activity COMT homozygotes were randomized to propranolol 240 mg/d or placebo. Primary outcomes were study feasibility (consent rate, protocol completion rate) and pain scores on study days 5 to 19. Secondary outcomes assessed pain and posttraumatic stress disorder symptoms 6 weeks postinjury; RESULTS: Seventy-seven percent (61/79) of eligible patients were consented and genotyped, and 77% (47/61) were genotype eligible and randomized. Ninety-one percent (43/47) tolerated study drug and completed primary outcome assessments. In intention-to-treat and per-protocol analyses, patients randomized to propranolol had worse pain scores on study days 5 to 19
UR  - http://dx.doi.org/10.1097/AJP.0000000000000086
ER  -